A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency naïve Pre-pubertal Children With Growth Hormone Deficiency
Latest Information Update: 04 Aug 2025
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
 - Indications Somatotropin deficiency
 - Focus Adverse reactions; Therapeutic Use
 - Acronyms REAL 3
 - Sponsors Novo Nordisk
 
Most Recent Events
- 11 Oct 2024 Status changed from recruiting to completed.
 - 18 Sep 2024 This trial has been completed in Slovenia ,according to the European Clinical Trials Database record.
 - 28 Oct 2023 This trial has been completed in Germany (Date of the global end of the trial: 02-Oct-2023), according to the European Clinical Trials Database record.